Profil
Judith Ng-Cashin served as the Chief Medical Officer at AOBiome Therapeutics, Inc. She also served as the Chief Medical Officer and Executive Vice President at Eagle Pharmaceuticals, Inc. Prior to her professional roles, she earned an undergraduate degree from Duke University and a doctorate from Rush Medical College.
Anciens postes connus de Judith Ng-Cashin
| Sociétés | Poste | Fin |
|---|---|---|
| EAGLE PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 27/12/2021 |
AOBiome Therapeutics, Inc.
 AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Directeur Technique/Scientifique/R&D | - |
Formation de Judith Ng-Cashin
| Duke University | Undergraduate Degree |
| Rush Medical College | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| EAGLE PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Health Technology |
